NMRK2

Across TCGA pan-cancer cohorts, NMRK2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NMRK2 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher NMRK2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NMRK2 expression acts as an unfavorable survival marker.

CESC, COAD, and MESO are the cancer types where NMRK2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	All	0.132	0.875	<.001	24	view →
COAD	OS	Median	All	0.111	0.871	<.001	24	view →
MESO	OS	Median	All	0.130	0.557	.019	18	view →
SKCM	DFS	Median	All	0.132	0.761	<.001	11	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

NMRK2–CESC (OS)

Open the CESC breakdown →